Press Releases

InVivo Therapeutics Announces Call Notice for Exercise of Warrants and Partial Termination of Warrant Exchange Offer

Published: May 23, 2013

CAMBRIDGE, Mass. (May 3, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that it has issued a call notice for the early exercise of warrants issued to investors on October 26, 2010, November 10, 2010 and December 3, 2010 (the “Investor Warrants”). Under the terms of the Investor Warrants, the Company has the right to call for an early exercise when the Company’s closing stock price equals or exceeds $2.80 per share for twenty consecutive trading days, which occurred on May 2, […]

View Article
InVivo Therapeutics Sponsors 8th Annual Working 2 Walk Spinal Cord Injury Symposium

Published: May 16, 2013

CAMBRIDGE, Mass. (May 16, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company is the Title Sponsor of the 8th annual Working 2 Walk Science & Advocacy Symposium taking place September 27-28, 2013 at the Boston Convention & Exhibit Center in Boston, MA. Working 2 Walk is an annual event held by Unite 2 Fight Paralysis to bring together spinal cord injury research scientists, practitioners, investors and consumers for a discussion of current research and strategies that will accelerate progress […]

View Article
InVivo Therapeutics Reports First Quarter 2013 Financial Results, Provides Business Update

Published: May 9, 2013

CAMBRIDGE, Mass. (May 9, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the three months ended March 31, 2013 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic spinal cord injury. Today there is no effective treatment for the spinal cord for paralysis caused […]

View Article
InVivo Therapeutics Named a 2013 “Best Places to Work” Winner by Boston Business Journal

Published: May 2, 2013

CAMBRIDGE, Mass. (May 2, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has been named one of the Best Places to Work in Massachusetts by the The Boston Business Journal in its eleventh annual regional awards program. The honor recognizes the Company’s achievements in creating a positive work environment that attracts and retains employees through a combination of employee satisfaction, working conditions and company culture. InVivo Therapeutics was one of over 400 companies to qualify for consideration based on […]

View Article
InVivo Enters Commercialization Phase, Adds John A. McCarthy to Board of Directors

Published: April 23, 2013

CAMBRIDGE, Mass. (April 23, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that John A. McCarthy, Chief Executive Officer at CryoXtract, has joined InVivo’s Board of Directors. McCarthy has also been appointed as Chair of the Board’s Audit committee, and has become a member of the Governance, Nominating and Compensation committee. “We’ve turned the corner on development and we’re full steam ahead on commercialization for multiple products. We expect that two 510(k) neurological devices will enter the market by the end 2014. […]

View Article
InVivo Therapeutics Announces Warrant Exchange Offer with Intent to Up-List to a National Securities Exchange

Published: April 8, 2013

CAMBRIDGE, Mass. (April 8, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that it has commenced an offer to exchange outstanding warrants issued in 2010 to purchase approximately 15.0 million common shares (“2010 warrants”) for new warrants. The 2010 warrants have exercise prices of $1.40 and $1.00 per share and expire in 2015. One of the primary reasons for the offering is to facilitate the Company’s plans to uplist its stock to a national securities exchange such as NASDAQ or NYSE MKT. […]

View Article
InVivo Therapeutics Receives Approval from FDA for First Human Trial Using Biomaterials for Traumatic Spinal Cord Injury

Published: April 5, 2013

CAMBRIDGE, Mass. (April 5, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI. With this approval, InVivo intends to commence a first-in-man clinical study in the next few months that will test safety and performance of its biopolymer scaffold in five patients. The Company expects the study […]

View Article
InVivo Therapeutics Receives Humanitarian Use Device Designation for Spinal Cord Injury Treatment

Published: April 4, 2013

CAMBRIDGE, Mass. (April 4, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration (FDA) for Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product. HUD designation covers devices that treat rare, ‘orphan’ diseases or conditions. InVivo has received designation for the use of its biopolymer scaffolding for the treatment of recent complete spinal cord injury (no motor or sensory function) that does not involve penetrating […]

View Article
InVivo Therapeutics Sponsors 2013 RISE Above Paralysis Gala

Published: March 14, 2013

CAMBRIDGE, Mass. (March 14, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has renewed its support for the Greater Boston Chapter of the National Spinal Cord Injury Association (NSCIA), a non-profit organization that offers programs and services to those with spinal cord injury and disease. InVivo will serve as a Premier sponsor at the RISE Above Paralysis Gala this Saturday, March 16, 2013, an annual event hosted by the Greater Boston Chapter of the NSCIA. The evening will bring […]

View Article
InVivo Therapeutics Reports 2012 Financial Results, Provides Business Update

Published: March 13, 2013

CAMBRIDGE, Mass. (March 13, 2013) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the year ended December 31, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic SCI. Today there is no effective treatment for the spinal cord for paralysis caused by SCIs, […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.